You are here
ACADEMIC PHARMACEUTICALS
UEI: ZC8ZATDAATL9
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Developing a Parenteral Formulation ofMetolazone
Amount: $158,460.00Project Summary AbstractMetolazone is a quinazoline sulfonamide with potent thiazide like diuretic activity on the cortical diluting segmentas well as diuretic action on the proximal tubuleMetolazoneo ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Soestolol: A potentially short acting Type III anti-arrhythmic
Amount: $153,260.00Project Summary AbstractAn ester of a beta blockeresmololwas introducedyears ago to facilitate the use of beta blockers in the acute care settingIV beta blockers have a long half life and this discour ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
A Safer Cardiac Abuse Deterrent Formulation of Methadone
Amount: $149,980.00Project Summary Methadone is a synthetic opioid used to treat pain and as maintenance therapy for opiate addicted individuals Methadone does not have the euphoric properties of morphine and thus is ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Reducing Methadone's Arrhythmic potential
Amount: $102,910.00DESCRIPTION (provided by applicant): Methadone is an important long-term maintenance therapy for drug addiction and currently is frequently used for analgesia. However, methadone prolongs the QT inter ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Pediatric Acceptable Formulation of Amiodarone
Amount: $100,188.00DESCRIPTION (provided by applicant): IV amiodarone is the first line therapy for life threatening ventricular as well as supraventricular arrhythmias. However, the Tween 80 and benzyl alcohol diluent ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Digoxin Chiral Isolates as Improved Pharmaceuticals
Amount: $102,008.00DESCRIPTION (provided by applicant): Digoxin is the first line pharmacologic therapy for CHF and AF. Digoxin increases cardiac contractility and blocks conduction through the AV node slowing the ventr ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health